Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Astera Labs, Inc.ALAB · Entity 1853 | Chief Financial Officer | February 17, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Astera Labs, Inc.
Report date February 17, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 192,083 |
Ending reported balance
After 2026-02-17 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-02-17 · Sale · Disposed 753 · Balance 203,331 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.1000 to $122.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-02-17 · Sale · Disposed 4,250 · Balance 199,081 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.3200 to $123.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-02-17 · Sale · Disposed 3,556 · Balance 195,525 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.3300 to $124.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-02-17 · Sale · Disposed 2,281 · Balance 193,244 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.3500 to $125.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-02-17 · Sale · Disposed 1,161 · Balance 192,083 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectBy Tate Trust | 450,281 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 450,281 F6: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.1000 to $122.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.3200 to $123.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.3300 to $124.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.3500 to $125.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 20, 2026 01:52 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,161 | $126.34 | $146,680.74 |
DisclosureSEC source: 0001399546-26-000004 · wk-form4_1771552333.xml · nonDerivative · entry 5 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,083 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:52 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 2,281 | $124.66 | $284,343.30 |
DisclosureSEC source: 0001399546-26-000004 · wk-form4_1771552333.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,244 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.3500 to $125.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:52 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 3,556 | $123.93 | $440,690.10 |
DisclosureSEC source: 0001399546-26-000004 · wk-form4_1771552333.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,525 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.3300 to $124.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:52 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 4,250 | $122.84 | $522,086.15 |
DisclosureSEC source: 0001399546-26-000004 · wk-form4_1771552333.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,081 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.3200 to $123.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:52 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 753 | $122.16 | $91,984.15 |
DisclosureSEC source: 0001399546-26-000004 · wk-form4_1771552333.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,331 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.1000 to $122.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:52 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GrantCommon Stock | 11,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001399546-26-000002 · wk-form4_1770767556.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,084 F1 · shares: These shares represent an award of restricted stock units ("RSUs") granted on February 6, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award provides that the RSUs shall vest as to 25% on February 15, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:21 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 3,238 | $143.52 | $464,703.19 |
DisclosureSEC source: 0001399546-25-000007 · wk-form4_1763587313.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,297 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.0000 to $143.1850, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:21 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 4,459 | $144.53 | $644,478.00 |
DisclosureSEC source: 0001399546-25-000007 · wk-form4_1763587313.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,535 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.0000 to $144.0600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:21 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 2,609 | $145.69 | $380,107.30 |
DisclosureSEC source: 0001399546-25-000007 · wk-form4_1763587313.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,994 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.0000 to $145.1000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:21 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,124 | $146.42 | $164,570.68 |
DisclosureSEC source: 0001399546-25-000007 · wk-form4_1763587313.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,603 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.0000 to $146.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:15 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000132 · wk-form4_1757708115.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 450,281 F1 · kind: Represents a bona fide gift of shares to a non-affiliated person. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 00:27 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 55,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000114 · wk-form4_1755736017.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 457,281 F4 · kind: On August 19, 2025, the Reporting Person transferred 55,785 shares of Issuer Common Stock to Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust") for no consideration. F5 · ownership.nature: These shares are owned directly by the Tate Trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 00:27 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 55,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000114 · wk-form4_1755736017.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,727 F4 · kind: On August 19, 2025, the Reporting Person transferred 55,785 shares of Issuer Common Stock to Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust") for no consideration. Read SEC document |
| August 18, 2025 Filed Aug 21, 2025 00:27 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 9,193 | $183.17 | $1,683,874.46 |
DisclosureSEC source: 0001736297-25-000114 · wk-form4_1755736017.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,512 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $183.4400 to $182.8700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2025 Filed Aug 21, 2025 00:27 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 9,668 | $183.83 | $1,777,310.01 |
DisclosureSEC source: 0001736297-25-000114 · wk-form4_1755736017.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,705 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $184.4400 to $183.4500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,065 | $192.52 | $205,029.11 |
DisclosureSEC source: 0001736297-25-000106 · wk-form4_1755203476.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 401,496 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $192.5000 to $192.5500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 32,374 | $191.92 | $6,213,095.06 |
DisclosureSEC source: 0001736297-25-000106 · wk-form4_1755203476.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 402,561 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $191.5000 to $192.4900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 66,561 | $190.82 | $12,700,863.84 |
DisclosureSEC source: 0001736297-25-000106 · wk-form4_1755203476.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 434,935 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $190.5000 to $191.4950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000102 · wk-form4_1754946599.xml · nonDerivative · entry 7 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 501,496 F8 · kind: Represents a bona fide gift of shares to a non-affiliated person. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 08, 2025 Filed Aug 20, 2025 21:02 UTC Amendment | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000108 · wk-form4a_1755723751.xml · nonDerivative · entry 6 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 501,496 F7 · kind: Represents a bona fide gift of shares to a non-affiliated person. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000102 · wk-form4_1754946599.xml · nonDerivative · entry 6 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · GlobalStar DAF Disclosed balance after: 7,500 F6 · kind: Represents a bona fide gift of shares to GlobalStar DAF. F7 · ownership.nature: These shares are directly owned by the GlobalStar DAF, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000102 · wk-form4_1754946599.xml · nonDerivative · entry 5 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 511,496 F6 · kind: Represents a bona fide gift of shares to GlobalStar DAF. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 34,125 | $173.82 | $5,931,723.53 |
DisclosureSEC source: 0001736297-25-000102 · wk-form4_1754946599.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 518,996 F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.5950 to $174.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 15,141 | $171.48 | $2,596,345.37 |
DisclosureSEC source: 0001736297-25-000102 · wk-form4_1754946599.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 553,121 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.0800 to $171.8500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 7,550 | $170.34 | $1,286,063.98 |
DisclosureSEC source: 0001736297-25-000102 · wk-form4_1754946599.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 568,262 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.0500 to $170.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 43,184 | $169.61 | $7,324,351.87 |
DisclosureSEC source: 0001736297-25-000102 · wk-form4_1754946599.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 575,812 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.0500 to $169.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 20, 2025 21:02 UTC Amendment | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000108 · wk-form4a_1755723751.xml · nonDerivative · entry 5 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 511,496 F6 · kind: Represents a bona fide gift of shares to a non-affiliated entity. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 20, 2025 21:02 UTC Amendment | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 34,125 | $173.82 | $5,931,723.53 |
DisclosureSEC source: 0001736297-25-000108 · wk-form4a_1755723751.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 518,996 F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.5950 to $174.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 20, 2025 21:02 UTC Amendment | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 15,141 | $171.48 | $2,596,345.37 |
DisclosureSEC source: 0001736297-25-000108 · wk-form4a_1755723751.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 553,121 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.0800 to $171.8500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 20, 2025 21:02 UTC Amendment | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 7,550 | $170.34 | $1,286,063.98 |
DisclosureSEC source: 0001736297-25-000108 · wk-form4a_1755723751.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 568,262 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.0500 to $170.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 20, 2025 21:02 UTC Amendment | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 43,184 | $169.61 | $7,324,351.87 |
DisclosureSEC source: 0001736297-25-000108 · wk-form4a_1755723751.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 575,812 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.0500 to $169.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 24, 2025 Filed Jul 30, 2025 01:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GrantCommon Stock | 43,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000093 · wk-form4_1753839069.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,373 F1 · shares: These shares represent an award of restricted stock units ("RSUs") granted on July 24, 2025 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award provides that the RSUs shall vest as to 25% on August 15, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:40 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 7,100 | $94.33 | $669,728.80 |
DisclosureSEC source: 0001628280-25-029091 · wk-form4_1748983198.xml · nonDerivative · entry 7 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 618,996 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.0400 to $94.6000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:40 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 3,968 | $92.96 | $368,861.31 |
DisclosureSEC source: 0001628280-25-029091 · wk-form4_1748983198.xml · nonDerivative · entry 6 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 626,096 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.5400 to $93.0600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:40 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 15,492 | $92.04 | $1,425,831.01 |
DisclosureSEC source: 0001628280-25-029091 · wk-form4_1748983198.xml · nonDerivative · entry 5 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 630,064 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.5200 to $92.5100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:40 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 204,954 | $90.75 | $18,599,759.96 |
DisclosureSEC source: 0001628280-25-029091 · wk-form4_1748983198.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 645,556 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.5200 to $91.5000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:40 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 156,288 | $90.06 | $14,076,047.46 |
DisclosureSEC source: 0001628280-25-029091 · wk-form4_1748983198.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 850,510 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.5200 to $90.5100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:40 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 92,200 | $89.05 | $8,210,271.70 |
DisclosureSEC source: 0001628280-25-029091 · wk-form4_1748983198.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,006,798 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.5200 to $89.5100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:40 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 19,998 | $88.14 | $1,762,707.71 |
DisclosureSEC source: 0001628280-25-029091 · wk-form4_1748983198.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,098,998 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.5200 to $88.5100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 16, 2025 Filed May 21, 2025 01:13 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 3,979 | $90.33 | $359,440.18 |
DisclosureSEC source: 0001736297-25-000040 · wk-form4_1747789985.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,135 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.2400 to $90.4200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2025 Filed May 21, 2025 01:13 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 4,247 | $90.67 | $385,086.53 |
DisclosureSEC source: 0001736297-25-000040 · wk-form4_1747789985.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,114 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.4250 to $91.4200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2025 Filed May 21, 2025 01:13 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 881 | $92.16 | $81,188.56 |
DisclosureSEC source: 0001736297-25-000040 · wk-form4_1747789985.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,361 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.7300 to $92.5550, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:34 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 125,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000017 · wk-form4_1740785673.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 1,118,996 F5 · kind: Represents a bona fide gift of shares to a non-affiliated entity. F2 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:34 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 125,800 | $82.53 | $10,382,890.42 |
DisclosureSEC source: 0001736297-25-000017 · wk-form4_1740785673.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By CRUT Trust Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.5000 to $82.8200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by the CRUT Trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:34 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 125,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000017 · wk-form4_1740785673.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By CRUT Trust Disclosed balance after: 125,800 F1 · kind: Represents a bona fide gift of shares to Michael T Tate and Jeanne Larue Tate as Trustees of the GlobalStar 2025 CRUT (the "CRUT Trust"), a charitable remainder unitrust. F3 · ownership.nature: These shares are owned directly by the CRUT Trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:34 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 125,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-25-000017 · wk-form4_1740785673.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 1,244,796 F1 · kind: Represents a bona fide gift of shares to Michael T Tate and Jeanne Larue Tate as Trustees of the GlobalStar 2025 CRUT (the "CRUT Trust"), a charitable remainder unitrust. F2 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:51 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 34,474 | $92.07 | $3,174,028.07 |
DisclosureSEC source: 0001736297-25-000009 · wk-form4_1740095492.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,242 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.8700 to $92.6700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 22:08 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-24-000068 · wk-form4_1734127681.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 1,370,596 F1 · kind: Represents a bona fide gift of shares to a non-affiliated person. F2 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 22:08 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-24-000068 · wk-form4_1734127681.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 1,380,596 F1 · kind: Represents a bona fide gift of shares to a non-affiliated person. F2 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 22:08 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-24-000068 · wk-form4_1734127681.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 1,390,596 F1 · kind: Represents a bona fide gift of shares to a non-affiliated person. F2 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.